Advertisement
"The name change is an important step in our branding as a public company.We are returning to the name that I founded the company under in 2000,"commented Jonathan Houssian, the CEO and founder of RxElite. "This is anotherkey step in our plan to achieve significant year over year growth."
Advertisement
About RxElite, Inc.
RxElite, Inc. develops, manufactures, and markets generic prescriptiondrug products in specialty generic markets. These markets include products inthe areas of anesthesia, sterile liquid dose drugs (including respiratoryinhalation drugs, ophthalmics, and injectable drugs), and transdermal patchproducts.
Safe Harbor Statement
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 involving known andunknown risks, delays, and uncertainties that may cause our actual results orperformance to differ materially from those expressed or implied by theseforward-looking statements. These risks, delays, and uncertainties include,but are not limited to: risks associated with the uncertainty of futurefinancial results, our reliance on our sole supplier, the limiteddiversification of our product offerings, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission. The Company undertakes no obligation toupdate any forward-looking statements.Contact: Corporate Information Ph: (208) 288-5550 Toll Free: (800) 414-1901 Fax: (208) 288-1191 Investor Relations Charlie Forshee, 215-885-4981 [email protected] Segue Ventures LLC
SOURCE RxElite, Inc.
